Unstable angina is ischemic chest pain that occurs at rest, is new in onset, or has suddenly become more frequent and severe without a rise in cardiac troponin — and the information that drives safe care planning is a five-part risk snapshot taken on arrival: symptom pattern, ECG changes, troponin trend, bleeding risk, and comorbidity. Everything that follows — monitoring, drug timing, and discharge timing — hangs on those five data points. Miss any one, and the plan can fail in a predictable way, most often by sending home a patient whose first troponin was normal but whose second was not, or by continuing an anticoagulant through an invasive procedure without a plan to stop it first.

This is general educational information for clinicians and students, not a diagnosis or treatment plan for any individual patient. Guideline-recommended care shifts over time; verify doses and pathways against the current American Heart Association/American College of Cardiology or European Society of Cardiology guidance your institution follows.

Classify the Presentation Before You Plan Anything Else

Unstable angina sits inside acute coronary syndrome, and getting the label right determines every downstream choice. The 2020 European Society of Cardiology non-ST-elevation ACS guideline and the 2021 AHA/ACC chest pain guideline both separate patients by troponin: a rise or fall in high-sensitivity cardiac troponin with ischemic symptoms marks NSTEMI, while unstable angina keeps troponin negative but retains the classic clinical pattern of rest pain, new-onset severe angina, or accelerating angina. Ask three questions in order — is the pain ischemic in character, is it new or accelerating, and is troponin negative across serial draws.

The American Heart Association's 2014 NSTE-ACS guideline puts unstable angina alongside NSTEMI under one umbrella and drives the same initial pathway: aspirin, anticoagulation, ECG within 10 minutes of arrival, and serial troponin. That detail matters for planning because a provider who treats unstable angina as "just angina" may skip the anticoagulant that the guideline actually recommends. According to the AHA's 2014 guideline, anticoagulation with fondaparinux, enoxaparin, or unfractionated heparin should be chosen based on bleeding and renal risk, not on whether troponin turned positive.

One widely reproduced numeric anchor is the Thrombolysis in Myocardial Infarction risk score. TIMI assigns one point each for age 65 or older, three or more coronary risk factors, known coronary stenosis of 50% or more, aspirin use in the past week, severe angina in the past 24 hours, ST deviation of 0.5 mm or more, and a positive cardiac marker — a 0-to-7 scale. A score of 0–2 is often considered lower risk; 3–4 intermediate; 5–7 higher. Treat the score as a conversation starter, not a discharge ticket.

Planning error number one, according to the AHA 2014 guidance, is anchoring on a single normal troponin. Serial sampling at 0 and 3–6 hours is standard, and the European Society of Cardiology's 2020 guideline permits a 0/1-hour high-sensitivity algorithm when the assay supports it. Before you build any care plan, write the classification, the troponin numbers with times, and the ECG findings on the same page.

Match Monitoring Intensity to the Patient's Actual Risk

Monitoring is where care plans are most often overbuilt or underbuilt. The American Heart Association's 2014 NSTE-ACS guideline recommends continuous ECG monitoring for patients with ongoing symptoms, hemodynamic instability, or arrhythmia risk, but does not require it for every low-risk patient in a fully equipped observation unit with telemetry access. Match the monitoring to the score and the rhythm history, not to the diagnosis label alone.

Bedside planning should also account for oxygen. Routine supplemental oxygen for a patient with an oxygen saturation above 90% is not recommended by contemporary guidelines; the reflex to put every chest-pain patient on nasal cannula adds an alarm that can mask a real desaturation trend. Document oxygen saturation at rest and with ambulation instead. If the patient desaturates under 90% at rest, continuous pulse oximetry and a documented escalation threshold belong in the plan.

Comorbidity burden is a planning input, not a footnote. The European Society of Cardiology's 2020 guideline and its 2023 focused update emphasize that the choice between an early invasive strategy and a conservative one depends on age, frailty, renal function, and patient preference. A care plan for a 48-year-old with ongoing rest pain looks nothing like one for an 86-year-old with advanced dementia and a hemoglobin of 9 g/dL, even when the diagnosis is identical.

Write the monitoring plan in four lines: what is monitored (telemetry, pulse oximetry, pain score), how often, what triggers escalation, and who owns each trigger. At a typical community hospital, telemetry capacity is finite, so the plan should say what happens if telemetry is full — an honest, concrete contingency that most templates never include. A monitoring plan without an escalation owner is a wish.

Build the Antithrombotic and Anti-ischemic Plan Around Bleeding Risk

Every antithrombotic decision in unstable angina is a trade against bleeding, and the care plan should show the trade on paper. The American Heart Association's 2014 NSTE-ACS guideline recommends aspirin 162–325 mg chewed for initial treatment and indefinite low-dose aspirin afterward, plus an anticoagulant chosen by ischemia and bleeding risk. The European Society of Cardiology's 2020 guideline puts aspirin initial loading lower, at 150–300 mg, and recommends a P2Y12 inhibitor with default 12-month dual antiplatelet therapy in most patients who undergo stenting.

The bleeding-risk estimate is the part most often left blank. The CRUSADE bleeding score, published in Circulation in 2009, assigns points across baseline hematocrit, creatinine clearance, heart rate, systolic blood pressure, sex, congestive heart failure and prior vascular disease signs, giving a 0–100 scale that maps to bleeding risk categories. Low risk is roughly 20 or below, moderate 21–40, high 41–60, and very high above 60. The numbers are worth writing next to the drug because a high score is a reason to favor fondaparinux or bivalirudin-like strategies and to reconsider the duration of triple therapy.

Practical drug-planning items that get skipped: the creatinine clearance used to dose enoxaparin, the last dose and timing of any home anticoagulant, whether the patient received a P2Y12 inhibitor from another hospital or a previous clinician, and whether the patient has a drug-eluting or bare-metal stent. Each item changes the plan. The 2014 AHA guideline notes that patients already on aspirin at home still get the initial chewed dose in the emergency department.

Write every antithrombotic as a line item with drug, dose, route, start time, stop condition, and the monitoring lab. For heparin, that means aPTT or anti-Xa per your institution's protocol; for enoxaparin in reduced renal function, that means anti-Xa peak. If the anticoagulant is stopped for a procedure, record the stop time and re-start time on the same line — the procedure note alone will not carry it forward to the next shift.

Decide on an Invasive Versus Conservative Strategy and Write the Timing

The strategic fork in unstable angina care is whether the patient goes to the catheterization lab during the admission or whether care stays medical with later evaluation. According to the European Society of Cardiology's 2020 non-ST-elevation ACS guideline, an immediate invasive strategy within two hours applies to very-high-risk patients such as those with hemodynamic instability or refractory chest pain, while high-risk features such as a rising troponin pattern or dynamic ST changes point toward an invasive strategy within 24 hours.

The American Heart Association's 2014 NSTE-ACS guideline takes a similar but distinct stance: an early invasive strategy is recommended for patients with elevated risk features, and a conservative strategy is reasonable for patients who are not candidates for revascularization or who prefer it after informed discussion. A low-risk patient with a negative troponin series, no ST change, and a TIMI score of 1 or 2 may be managed conservatively, but a plan that says "conservative" without specifying a follow-up stress test or coronary CT timing is incomplete.

The timing delay is a real planning trap. Chesnokova and colleagues, in Radiology: Cardiothoracic Imaging, reported that patients whose symptoms resolved but who still had significant coronary disease often waited longer for invasive evaluation than guideline windows suggest; the finding is that the window starts at presentation, not when the patient looks comfortable. Plan the timing from the first ECG, and note the clock start in the chart so the next team does not restart it.

Include a stent-era contingency in the plan. If the plan is "catheterization within 24 hours, then dual antiplatelet therapy for 12 months if a stent is placed," the paragraph that covers discharge must say what happens if the patient has no insurance, cannot afford the P2Y12 inhibitor, or has a bleeding problem that changes the duration. The 2020 ESC guideline's 2023 focused update lets clinicians shorten or modify dual antiplatelet therapy in high-bleeding-risk patients, and the plan should say which pathway this patient is on before it matters.

Make Discharge Timing a Rule, Not a Feeling

Discharge timing is the most frequently poorly documented element in an unstable angina care plan because it often defaults to "when the patient feels better." A workable rule uses clinical stability plus a completed test: symptom-free for at least 24 hours, no new arrhythmia, stable troponin, and a documented plan for the next test or visit. If any of those four are missing, the discharge is premature — state that plainly in the plan and set the next reassessment time.

The Canadian Cardiovascular Society's 2020 acute coronary syndrome guidelines are useful here because their risk rationale is explicit: low-risk patients can be discharged after a negative troponin series and typically receive an outpatient stress test or CT coronary angiography within days rather than during the admission. The assumption behind that pathway is a follow-up appointment already scheduled before discharge, not a referral call left for the patient to make. Build the appointment into the discharge checklist; the plan fails when the patient leaves with a phone number and no date.

Discharge instructions should also name the specific symptom that should bring the patient back — chest pain at rest, pain lasting more than 20 minutes despite rest, or syncope — with the instruction to call emergency services. According to the American Heart Association's patient-education materials, the common failure is that patients interpret "no pain right now" as "better" and delay care for recurring pain. A one-sentence return-precaution written in the patient's own language, with the number to call, is not padding; it's the part that changes outcomes.

Finally, document the follow-up med reconciliation at discharge. That means aspirin and P2Y12 doses with the intended duration, beta-blocker target dose or reason not reached, high-intensity statin per the 2020 ESC guideline, and renal-dose limits for any anticoagulant. If the patient cannot pay for a drug, the plan should name the substitute or the assistance program before discharge, since a prescription the patient cannot fill is a plan that fails quietly.

Screen for the Depression and Anxiety That Worsen Angina Outcomes

The psychological comorbidity of unstable angina is under-addressed in care plans and has real consequences. According to the American Heart Association's 2014 NSTE-ACS guideline and its 2020 scientific statement on mental health and cardiovascular disease, depression and anxiety are associated with worse adherence, delayed presentation, and higher readmission after acute coronary syndrome. The planning implication is concrete: screen with the PHQ-2, add the GAD-7 if positive, and note the score with the social-work referral on the same page as the medical plan.

Walk the Drug Interaction and Adherence List in Plain Language

Instability in unstable angina is often driven by something outside the coronary artery. The patient's current medications and habits should be reviewed for triggers: recent NSAID use, missed antihypertensive doses, stimulant use, cocaine exposure, thyrotoxicosis, and severe anemia. The American Heart Association's 2014 guideline notes that noncardiac causes and precipitating factors should be sought, and the plan should list the ones already checked and the ones still pending.

Adherence is a planning input, not patient blame. The World Health Organization's 2003 statement on adherence to long-term therapies frames the issue as a system property, and the practical question for the discharge plan is what the patient actually takes at home. If the patient states they stopped their statin three months ago because of cost, the discharge plan should re-address statin affordability rather than assume the outpatient provider will. Record the answer in the plan, not just in the social history.

Case Walkthrough: The Low-Score Patient Who Still Has Disease

A 58-year-old arrives with chest pressure at rest. The ECG has no ST change; the first high-sensitivity troponin is below the assay's sex-specific threshold, and the second is also negative four hours later. The initial TIMI score is 2 (age plus three risk factors, no aspirin use, pain at rest fewer than 24 hours ago). This looks low risk — and the temptation is to discharge after the second troponin without further testing.

The planning correction is that a normal troponin series does not rule out unstable plaque. The American Heart Association's 2014 guideline and the European Society of Cardiology's 2020 guideline both permit a conservative strategy in low-risk patients, but the ESC 2020 document and the 2021 AHA/ACC chest pain guideline pair conservatism with objective testing: a stress test or CT coronary angiography within days. A review by Chesnokova and colleagues in Radiology: Cardiothoracic Imaging points out that CT coronary angiography can identify obstructive disease in lower-risk patients before symptoms recur.

The plan for this patient should therefore read: discharge with aspirin, high-intensity statin, a beta-blocker if tolerated, a follow-up within 72 hours, and a stress test or CT angiography appointment with a date. The discharge rule (symptom-free for 24 hours plus a completed test) is satisfied only if the future testing is scheduled and recorded on the discharge form. That is the difference between a safe discharge and an unsafe one — not the troponin value, which was never positive.

FAQ

How quickly should the first ECG be done in unstable angina?

Within 10 minutes of first medical contact, which is the AHA 2014 NSTE-ACS recommendation and not a target to negotiate at the triage desk. A patient who waits 25 minutes for a 12-lead ECG effectively loses a quarter of the guideline window before any therapy decision is made. Repeat the ECG if symptoms recur during observation, because dynamic changes can appear after a normal initial tracing.

Is unstable angina the same as NSTEMI?

No. The distinction is the troponin trend: unstable angina has negative serial troponin with characteristic rest or accelerating chest pain, while NSTEMI has a rise or fall in troponin with ischemic symptoms. Both are grouped as non-ST-elevation acute coronary syndrome by the AHA's 2014 guideline, so they share aspirin, anticoagulation, and ECG pathways but not the same risk-framing language during patient communication.

Can a patient with unstable angina go home the same day?

Sometimes, but the discharge rule requires more than a calm patient. The patient must be symptom-free for at least 24 hours, stable on ECG, troponin negative across serial samples, and have a documented appointment for a stress test or CT angiography within days. A same-day discharge with a referral phone number but no dated appointment fails the safety rule the Canadian Cardiovascular Society's 2020 guidelines assume.

What bleeding-risk score should be used, and at what number does the plan change?

The CRUSADE score (published in Circulation in 2009) gives a 0–100 estimate, with roughly 20 or below as low, 21–40 as moderate, 41–60 as high, and above 60 as very high. Above 40, the plan should already reflect a bleeding-avoidance discussion: anticoagulant choice, duration of dual or triple therapy, and whether a radial procedure can reduce access-site bleeding. The number does not decide alone; it prompts the conversation and the documentation.

What happens if the hospital has no catheterization lab?

The plan is transfer, and the transfer plan should name the receiving center, the patient's hemodynamic status at departure, the drugs running during the trip, and the estimated arrival window. A common failure is that the transfer is treated as a disposition rather than a step with a clinical handoff, so the receiving team learns about anticoagulation timing and allergy history late. Write the handoff facts on the transfer form, not just in the chart.

Does depression after unstable angina actually change the care plan?

It changes adherence and readmission risk enough to warrant screening. The AHA's 2020 scientific statement on mental health and cardiovascular disease associates depression and anxiety with worse medication adherence and higher readmission after acute coronary syndrome, so the PHQ-2 screen belongs in the admission plan. A positive screen should produce a named referral and a documented follow-up, not a checkmark.

Is a single negative high-sensitivity troponin enough to rule out unstable angina?

No. Serial testing at 0 and 1 or 0 and 3–6 hours is what the assays were validated for, and the European Society of Cardiology's 2020 guideline's rapid algorithm still requires a repeat sample. A single negative value in a patient with ongoing rest pain is a reason for the next step, not a discharge. The classic planning error is treating the first result as the final answer.

This article is general educational information for clinicians and students; it is not a diagnosis, treatment plan, or a substitute for institutional protocol or the current guideline edition your hospital follows. Doses, thresholds, and pathways change over time — confirm them against the current AHA/ACC or ESC guidance and your local pharmacy and cardiology services before acting. For any patient in immediate danger, activate local emergency services and follow your institution's escalation pathway rather than this article.